What is NeuroStar?

Definition of NeuroStar

NeuroStar is a transcranial magnetic stimulation (TMS) device manufactured by Neuronetics (NASDAQ: STIM). It was the first TMS system to receive FDA clearance for treatment-resistant depression in 2008 and remains the most widely installed TMS platform in the United States. NeuroStar uses a figure-8 coil to deliver focused magnetic pulses to the left dorsolateral prefrontal cortex, the brain region associated with mood regulation. Standard treatment involves 36 sessions over 9 weeks. NeuroStar has the strongest insurance reimbursement track record and the largest clinical outcomes database in the TMS category.

How NeuroStar works

NeuroStar uses a TrueIron coil with patient-specific motor threshold mapping to determine treatment intensity. The standard protocol delivers 3,000 pulses per session over 19 minutes (or 3,750 pulses over 37 minutes for the intermittent theta-burst protocol). The patient sits in a chair while the coil is positioned on the scalp; treatment is non-invasive and requires no anesthesia.

The mechanism behind NeuroStar matters for physician buyers because different implementations of the same underlying technology can produce different clinical outcomes. Two devices both labeled as NeuroStar can vary in power output, depth precision, energy delivery efficiency, and patient comfort. Understanding the mechanism is the first step in evaluating which specific device implementation is right for your practice.

FDA regulatory status

FDA-cleared for major depressive disorder (2008), obsessive-compulsive disorder (2018), and anxious depression (2021).

FDA clearance is a baseline requirement for any device sold in the US, but clearance status alone doesn't tell you whether a specific device is appropriate for your practice. Always verify the specific clearance scope (which indications, which body areas, which patient populations) and check the FDA MAUDE database for adverse event trends before making a purchase decision. The FDA 510(k) pathway most aesthetic and rehabilitation devices use is based on substantial equivalence to predicate devices, not on independent clinical efficacy testing.

Primary clinical applications

Treatment of treatment-resistant major depressive disorder and adjacent psychiatric conditions.

Clinical applications drive purchasing decisions. The right device matches your patient population, practice volume, and the procedures you perform (or want to perform). Devices marketed for broad applications can underperform on any single application compared to specialized alternatives. Devices specialized for one application can be limiting if your practice mix changes. Match the device to your clinical reality, not the marketing brochure.

Comparison to alternative technologies

In the medical device market, NeuroStar is rarely the only option for the clinical problems it addresses. Most procedures can be performed with multiple competing technologies, each with different efficacy, safety, cost, and patient experience profiles. Understanding NeuroStar in isolation matters less than understanding how it compares to alternatives for your specific patient population and practice economics. Related technologies and concepts include tms, brainsway deep tms, dtms, each with their own clinical strengths and tradeoffs that may matter for your decision.

Devices using NeuroStar

The following devices in our coverage use NeuroStar as their primary technology. Each device profile includes pricing, clinical evidence, pros and cons, and head-to-head comparisons against alternatives.

Manufacturers in this technology category

The following manufacturers produce devices using NeuroStar or closely related technologies. Each profile covers company financials, technology platform, market position, and a list of relevant devices.

Why physicians need to understand this

For physicians evaluating capital equipment in this category, understanding NeuroStar helps separate marketing claims from clinical reality. Manufacturer sales reps tend to lean heavily on brand-specific terminology that obscures whether their device offers any meaningful technological advantage over alternatives. A working understanding of the underlying mechanism lets you read between the lines and ask better diligence questions.

The right diligence framework starts with the technology, then asks how a specific device implements it. Two devices using NeuroStar can have different clinical outcomes depending on power, depth control, applicator design, software refinement, and operator training. The technology is the foundation; the implementation determines the result. When you compare devices that all claim to use NeuroStar, focus on the implementation differences rather than the underlying category.

When you're evaluating a $50,000 to $250,000 capital purchase that uses NeuroStar, the questions to ask your sales rep are: how does this implementation differ from competitor implementations, what clinical evidence exists comparing them, what's the per-treatment economic outcome at realistic patient volume, and what's the failure mode when the device doesn't perform as expected. Marketing materials rarely answer those questions head-on. Asking them directly forces the rep to defend the device on its merits rather than its category.

Marketing red flags to watch for

Common red flags in marketing claims about NeuroStar: Overstated efficacy. Manufacturers often quote best-case clinical study results without disclosing the full population or failure rates. Misleading depth or power claims. Specifications that sound impressive may have no clinical correlate or may exceed safety thresholds. Cherry-picked competitor comparisons. Sales materials that compare a single dimension (like maximum treatment area) while ignoring dimensions where competitors are stronger. Off-label promotion. Manufacturers can only legally promote devices for FDA-cleared indications. Claims for unproven uses are a regulatory red flag. Verify every marketing claim against published clinical evidence and the FDA 510(k) database before making a purchase decision.

NeuroStar and Section 179 tax planning

Devices using NeuroStar typically qualify for Section 179 tax deduction, which lets practices deduct the full purchase price in the year the equipment is placed in service. For devices in the $50,000 to $250,000 range that's typical for this category, the Section 179 deduction can reduce after-tax cost by 30-40% in year one. The deduction applies to both new and used equipment as long as it's new to the buyer, which means refurbished devices using NeuroStar get the same tax treatment as new units. Read our complete Section 179 guide for tax planning details.

Buying considerations specific to NeuroStar

Beyond the technology itself, physicians evaluating devices that use NeuroStar should think carefully about three additional factors: manufacturer financial stability, secondary market depth, and clinical training availability.

Manufacturer financial stability matters more than the technology. A great device from a struggling manufacturer can become an expensive paperweight if the company stops supporting the platform, discontinues consumables, or fails entirely. Before committing capital, check the manufacturer's recent financial filings (for public companies) or estimated revenue trends (for private companies). Manufacturers under significant pressure may offer aggressive discounts, but the long-term support risk is real.

Secondary market depth. The depth of the used and refurbished market for a specific technology determines your exit options. Devices with active secondary markets (like Emsculpt Neo or Morpheus8) hold value and give you flexibility to upgrade or sell. Devices with thin secondary markets become illiquid investments that you can't easily exit if your practice direction changes.

Clinical training availability. The same device can produce different clinical outcomes in the hands of trained versus untrained operators. Before buying, confirm that training is available for all providers in your practice, that ongoing training resources exist as new protocols emerge, and that the manufacturer's training quality matches the technology's complexity. Devices with strong training ecosystems produce better patient outcomes and stronger ROI.